Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Free Cash Flow: 2011-2025

Historic Free Cash Flow for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to $29.1 million.

  • Mimedx Group's Free Cash Flow rose 49.77% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 19.81%. This contributed to the annual value of $65.4 million for FY2024, which is 98.62% up from last year.
  • Per Mimedx Group's latest filing, its Free Cash Flow stood at $29.1 million for Q3 2025, which was up 104.61% from $14.2 million recorded in Q2 2025.
  • In the past 5 years, Mimedx Group's Free Cash Flow ranged from a high of $29.1 million in Q3 2025 and a low of -$11.4 million during Q4 2021.
  • Moreover, its 3-year median value for Free Cash Flow was $14.2 million (2025), whereas its average is $13.3 million.
  • In the last 5 years, Mimedx Group's Free Cash Flow plummeted by 383.50% in 2022 and then skyrocketed by 1,944.59% in 2023.
  • Over the past 5 years, Mimedx Group's Free Cash Flow (Quarterly) stood at -$11.4 million in 2021, then surged by 45.05% to -$6.3 million in 2022, then spiked by 240.57% to $8.8 million in 2023, then soared by 109.41% to $18.5 million in 2024, then soared by 49.77% to $29.1 million in 2025.
  • Its Free Cash Flow stands at $29.1 million for Q3 2025, versus $14.2 million for Q2 2025 and $4.9 million for Q1 2025.